ZA200207864B - Vascular prothesis impregnated with crosslinked dextran. - Google Patents
Vascular prothesis impregnated with crosslinked dextran. Download PDFInfo
- Publication number
- ZA200207864B ZA200207864B ZA200207864A ZA200207864A ZA200207864B ZA 200207864 B ZA200207864 B ZA 200207864B ZA 200207864 A ZA200207864 A ZA 200207864A ZA 200207864 A ZA200207864 A ZA 200207864A ZA 200207864 B ZA200207864 B ZA 200207864B
- Authority
- ZA
- South Africa
- Prior art keywords
- dextran
- functionalized
- prosthesis
- solution
- support
- Prior art date
Links
- 229920002307 Dextran Polymers 0.000 title claims abstract description 127
- 230000002792 vascular Effects 0.000 title claims abstract description 43
- 238000000034 method Methods 0.000 claims abstract description 26
- 239000003431 cross linking reagent Substances 0.000 claims description 23
- 230000008569 process Effects 0.000 claims description 22
- 150000004676 glycans Chemical class 0.000 claims description 20
- 238000005470 impregnation Methods 0.000 claims description 19
- 229920001282 polysaccharide Polymers 0.000 claims description 19
- 239000005017 polysaccharide Substances 0.000 claims description 19
- 238000004132 cross linking Methods 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 8
- 239000003960 organic solvent Substances 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 6
- 150000007942 carboxylates Chemical class 0.000 claims description 5
- 239000003146 anticoagulant agent Substances 0.000 claims description 4
- 229940127219 anticoagulant drug Drugs 0.000 claims description 4
- 239000004014 plasticizer Substances 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 230000002924 anti-infective effect Effects 0.000 claims description 3
- 239000012678 infectious agent Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 52
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 33
- 230000035699 permeability Effects 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 23
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 239000011248 coating agent Substances 0.000 description 15
- 238000000576 coating method Methods 0.000 description 15
- 210000002889 endothelial cell Anatomy 0.000 description 15
- 101000628535 Homo sapiens Metalloreductase STEAP2 Proteins 0.000 description 13
- 102100026711 Metalloreductase STEAP2 Human genes 0.000 description 13
- 239000000499 gel Substances 0.000 description 11
- 150000008131 glucosides Chemical group 0.000 description 11
- 229920005654 Sephadex Polymers 0.000 description 10
- 239000004310 lactic acid Substances 0.000 description 10
- 235000014655 lactic acid Nutrition 0.000 description 10
- SHKUUQIDMUMQQK-UHFFFAOYSA-N 2-[4-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical compound C1OC1COCCCCOCC1CO1 SHKUUQIDMUMQQK-UHFFFAOYSA-N 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 239000005020 polyethylene terephthalate Substances 0.000 description 9
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 8
- 229960002897 heparin Drugs 0.000 description 8
- 229920000669 heparin Polymers 0.000 description 8
- 229920000139 polyethylene terephthalate Polymers 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 8
- -1 polypropylene Polymers 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 239000012894 fetal calf serum Substances 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 150000001720 carbohydrates Chemical group 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- 230000003068 static effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- KGSVNOLLROCJQM-UHFFFAOYSA-N 2-(benzylamino)acetic acid Chemical group OC(=O)CNCC1=CC=CC=C1 KGSVNOLLROCJQM-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 229920000295 expanded polytetrafluoroethylene Polymers 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 229920002239 polyacrylonitrile Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- UGTZMIPZNRIWHX-UHFFFAOYSA-K sodium trimetaphosphate Chemical compound [Na+].[Na+].[Na+].[O-]P1(=O)OP([O-])(=O)OP([O-])(=O)O1 UGTZMIPZNRIWHX-UHFFFAOYSA-K 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- FZWBNHMXJMCXLU-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC(O)C(O)C(O)C(O)C=O)O1 FZWBNHMXJMCXLU-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical class O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 101150110920 FRO1 gene Proteins 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical class O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 1
- 244000037640 animal pathogen Species 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000002391 anti-complement effect Effects 0.000 description 1
- 108010008730 anticomplement Proteins 0.000 description 1
- 239000003698 antivitamin K Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940041984 dextran 1 Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 235000019256 formaldehyde Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000000892 gravimetry Methods 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 230000001453 nonthrombogenic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000003058 plasma substitute Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 230000002885 thrombogenetic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 238000007631 vascular surgery Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/042—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/507—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials for artificial blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/06—Use of macromolecular materials
- A61L33/08—Polysaccharides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/02—Dextran; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Transplantation (AREA)
- Surgery (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Materials Engineering (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0004554A FR2807326B1 (fr) | 2000-04-10 | 2000-04-10 | Prothese vasculaire impregnee de dextrane reticule et/ou d'un derive fonctionnalise de dextane reticule et son procede de preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200207864B true ZA200207864B (en) | 2004-02-26 |
Family
ID=8849065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200207864A ZA200207864B (en) | 2000-04-10 | 2002-10-01 | Vascular prothesis impregnated with crosslinked dextran. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6991648B2 (de) |
| EP (1) | EP1272234B1 (de) |
| JP (1) | JP2003530158A (de) |
| AT (1) | ATE435038T1 (de) |
| AU (2) | AU4843401A (de) |
| CA (1) | CA2405947C (de) |
| DE (1) | DE60139118D1 (de) |
| ES (1) | ES2329335T3 (de) |
| FR (1) | FR2807326B1 (de) |
| HK (1) | HK1052308A1 (de) |
| WO (1) | WO2001076652A1 (de) |
| ZA (1) | ZA200207864B (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10223310A1 (de) * | 2002-05-24 | 2003-12-11 | Biotronik Mess & Therapieg | Verfahren zum Beschichten von Implantaten mit einer Polysaccharid-Lage |
| DE10329296B4 (de) * | 2003-06-24 | 2007-07-12 | Leibniz-Institut Für Polymerforschung Dresden E.V. | Beschichtungssystem für Biomaterialien |
| US7329531B2 (en) * | 2003-12-12 | 2008-02-12 | Scimed Life Systems, Inc. | Blood-tight implantable textile material and method of making |
| CN104725660A (zh) * | 2007-10-11 | 2015-06-24 | 国家健康与医学研究院 | 制备用于组织工程、细胞培养和细胞传递的多孔支架的方法 |
| RU2470671C1 (ru) * | 2011-07-06 | 2012-12-27 | Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова Федерального агентства по здравоохранению и социальному развитию" | Способ обработки текстильных изделий для сердечно-сосудистой хирургии |
| FR3005056B1 (fr) * | 2013-04-24 | 2016-04-01 | Ayawane | Hydrogel a base de polysaccharides natifs et/ou fonctionnalises, phosphates co-reticules |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2555589B1 (fr) * | 1983-11-30 | 1986-05-16 | Choay Sa | Nouveaux derives du dextrane a activites anticoagulante en anti-inflammatoire, leur procede de preparation et utilisation de ces derives en tant qu'anticoagulants et en tant que substituts du plasma sanguin |
| JPS60227763A (ja) * | 1984-04-27 | 1985-11-13 | 筏 義人 | 抗血栓性医用材料 |
| JPH07110893B2 (ja) * | 1984-11-30 | 1995-11-29 | 大西 靖彦 | マトリックス重合体の製法 |
| US5693625A (en) * | 1989-03-09 | 1997-12-02 | Therapeutiques Substitutives | Method of regenerating cells and tissues using functionalized dextrans |
| KR920000459B1 (ko) * | 1989-12-13 | 1992-01-14 | 재단법인 한국화학연구소 | 다당류 유도체가 도포된 인공혈관과 그 제조방법 |
| US5851229A (en) * | 1996-09-13 | 1998-12-22 | Meadox Medicals, Inc. | Bioresorbable sealants for porous vascular grafts |
| DE69931371T2 (de) * | 1998-07-10 | 2007-05-24 | Encelle, Inc. | Methoden zur verbesserung der vaskularisierung und förderung der wundheilung |
| AU3615700A (en) * | 1999-03-04 | 2000-09-21 | United States Surgical Corporation | Scar reduction |
| US6379382B1 (en) * | 2000-03-13 | 2002-04-30 | Jun Yang | Stent having cover with drug delivery capability |
| US6977821B2 (en) * | 2003-03-20 | 2005-12-20 | 3Com Corporation | Backplane apparatus and board for use therewith |
| US7035115B2 (en) * | 2003-04-11 | 2006-04-25 | Rockwell Automation Technologies, Inc. | Multi-axis motor control with high voltage backplane |
| US6966784B2 (en) * | 2003-12-19 | 2005-11-22 | Palo Alto Research Center Incorporated | Flexible cable interconnect assembly |
-
2000
- 2000-04-10 FR FR0004554A patent/FR2807326B1/fr not_active Expired - Fee Related
-
2001
- 2001-03-30 AU AU4843401A patent/AU4843401A/xx active Pending
- 2001-03-30 AT AT01921442T patent/ATE435038T1/de not_active IP Right Cessation
- 2001-03-30 EP EP01921442A patent/EP1272234B1/de not_active Expired - Lifetime
- 2001-03-30 WO PCT/FR2001/000964 patent/WO2001076652A1/fr active IP Right Grant
- 2001-03-30 ES ES01921442T patent/ES2329335T3/es not_active Expired - Lifetime
- 2001-03-30 US US10/240,989 patent/US6991648B2/en not_active Expired - Fee Related
- 2001-03-30 DE DE60139118T patent/DE60139118D1/de not_active Expired - Fee Related
- 2001-03-30 AU AU2001248434A patent/AU2001248434B2/en not_active Ceased
- 2001-03-30 JP JP2001574167A patent/JP2003530158A/ja active Pending
- 2001-03-30 CA CA002405947A patent/CA2405947C/fr not_active Expired - Fee Related
-
2002
- 2002-10-01 ZA ZA200207864A patent/ZA200207864B/en unknown
-
2003
- 2003-06-24 HK HK03104539.7A patent/HK1052308A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1272234B1 (de) | 2009-07-01 |
| FR2807326A1 (fr) | 2001-10-12 |
| CA2405947A1 (fr) | 2001-10-18 |
| CA2405947C (fr) | 2009-09-29 |
| AU4843401A (en) | 2001-10-23 |
| DE60139118D1 (de) | 2009-08-13 |
| WO2001076652A1 (fr) | 2001-10-18 |
| US20030163186A1 (en) | 2003-08-28 |
| US6991648B2 (en) | 2006-01-31 |
| ES2329335T3 (es) | 2009-11-25 |
| AU2001248434B2 (en) | 2004-10-07 |
| JP2003530158A (ja) | 2003-10-14 |
| FR2807326B1 (fr) | 2002-08-23 |
| HK1052308A1 (zh) | 2003-09-11 |
| EP1272234A1 (de) | 2003-01-08 |
| ATE435038T1 (de) | 2009-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0941131B1 (de) | Bioresorbierbare dichtungsmassen für poröse künstliche gefässen | |
| Ratner et al. | Synthetic hydrogels for biomedical applications | |
| US5986168A (en) | Prosthesis containing bioabsorbable materials insolubilized without chemical reagents and method of making the same | |
| Miyamoto et al. | Tissue biocompatibility of cellulose and its derivatives | |
| Matsuda et al. | Influence of glycosaminoglycans on the collagen sponge component of a bilayer artificial skin | |
| EP0512122A1 (de) | Implantatmaterial | |
| US20050287193A1 (en) | Wound dressing made of chitin and alginate and method for forming the same | |
| WO1984000302A1 (en) | Biocompatible, antithrombogenic materials suitable for reconstructive surgery | |
| CN113082295B (zh) | 一种基于皮肤源脱细胞基质衍生支架及其构建方法 | |
| CA2321890A1 (en) | Sulphated hyaluronic acid and sulphated derivatives thereof covalently bound to polyurethanes, and the process for their preparation | |
| KR100440239B1 (ko) | 상처 치료용 수화겔의 제조방법 | |
| Kim et al. | Effect of PVA concentration on strength and cell growth behavior of PVA/gelatin hydrogels for wound dressing | |
| CN104548201B (zh) | 一种角膜组织修复材料及其制备方法 | |
| AU2001248434B2 (en) | Vascular prosthesis impregnated with crosslinked dextran | |
| Lee et al. | Effect of forms of collagen linked to polyurethane on endothelial cell growth | |
| KR100545404B1 (ko) | 키틴 또는 키토산의 나노섬유(초극세섬유)를 구성성분으로하는 부직포 | |
| JPH09192211A (ja) | コラーゲンゲル、コラーゲンシートおよびその製造方法 | |
| EP1207917B1 (de) | Dichtungsmittel für gefässprothesen | |
| US20070059473A1 (en) | Sheet-like covering member used for implant medical device | |
| EP0282091A2 (de) | Medizinisches Erzeugnis mit gesteuerter Heparinabgabe | |
| CN116082717B (zh) | 水凝胶、血管纤维骨架及其制备方法和应用 | |
| EP1754495A2 (de) | Flächiges Gebilde zur Abdeckung von medizinischen Geräten | |
| RU2714671C1 (ru) | Трехмерный пористый композитный материал и способ его получения | |
| CN115704047A (zh) | 一种用于植入材料体外细胞的毒性检测方法 | |
| RO137220A0 (ro) | Biomaterial compozit poros cu proprietăţi de stimulare a regenerării ţesutului dermic |